Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

20101,629 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet

Volume 376, Issue 9737, pp. 235-244

Field-Weighted Citation Impact: 72.08